Annual influenza epidemics in the United States cause hundreds of thousands of hospitalizations.

Global influenza and COVID-19 activity stayed low in late October 2025. COVID-19 was more common in northern regions, while influenza spread mainly in tropical areas.

On the European Laboratory Day, held on 5 November, the European Commission marks one year of improved coordination on surveillance data thanks to the EU reference laboratories (EURLs).

In self‐controlled case series studies, laboratory‐confirmed influenza infection was associated with an elevated risk of acute myocardial infarction and stroke during the first 1 month.

Influenza 2024–2025 season in France was characterized by prolonged duration, unusual co-circulation of all three viruses (A(H1N1)pdm09, A(H3N2), B/Victoria) with several subclades, and substantial healthcare impact.

Launched as an interactive dashboard, ERVISS offers weekly integrated data on influenza, RSV and SARS-CoV-2 across the EU/EEA and the WHO European Region.

High-dose inactivated influenza vaccine has been shown to provide protection against influenza that is superior to that with the standard dose.

Each year, RSV causes an estimated 3.6 million RSV-associated hospitalisations and approximately 100.000 RSV-attributable deaths in children under 5 years of age worldwide .